[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577961":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Besancon","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with severe thrombocytopenia",null,"Patients with haematological malignancies who have severe thrombocytopenia associated with bone marrow failure requiring platelet transfusion and who are able to self-assess bleeding events.",[13],"Other: Self-assessment of bleeding events",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Self-assessment of bleeding events","After each transfusion, the patient completes a daily bleeding event self-assessment (adapted from the WHO bleeding event scale) until the next transfusion or over a period of 10 days.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Charline Vauchy, PhD.","CONTACT","+33381218875","cvauchy@chu-besancon.fr",[26],{"facility":27,"status":28,"city":29,"state":10,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"CHU Besançon","RECRUITING","Besançon","25000","France","FR",{"type":34,"coordinates":35},"Point",[36,37],6.01815,47.24878,{"lat":37,"lon":36},[40],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100577961","clinical-efficacy-of-platelet-transfusion-100577961",false,"NCT06805097","Clinical Efficacy of Platelet Transfusion","ECLAT","Inclusion Criteria:\n\n* Patients with haematological malignancies or bone marrow aplasia with severe thrombocytopenia due to bone marrow failure related to the disease or treatments received\n* Severe thrombocytopenia requiring transfusion\n* Patient able to self-assess bleeding events\n* Non-opposition of the subject to participate in the study\n* Registered with the French social security system or benefiting from such a system.\n\nExclusion Criteria:\n\n* Acute promyelocytic leukaemia\n* Curative dosage of anticoagulants\n* Treatment with antiplatelet agents\n* Patient with proven thrombocytopenia of immunological origin, or disseminated intravascular coagulation\n* Patients with a clinically significant haemorrhagic event (WHO grade 2) in the 48 hours prior to transfusion\n* Indication for deplasmatised, cryopreserved and reduced-volume PCs\n* Patient refusing transfusion of labile blood products\n* Pregnant women or breast-feeding mothers\n* Adults subject to a legal protection measure or unable to express their consent\n* Persons deprived of their liberty by a judicial or administrative decision; persons under compulsory psychiatric care; persons admitted to a health or social care institution for purposes other than research\n* Subject in the exclusion period of another study","ALL","18 Years",{"count":53,"type":54},343,"ESTIMATED","OBSERVATIONAL","The aim of this study is to analyze the effect of the storage time of platelet concentrates on the occurrence of bleeding events during prophylactic platelet transfusions in patients with hematological malignancies.",[58,59],"Thrombocytopaenia","Haematological Malignancies",[61,62,63],"platelet concentrate","transfusion","haemorrhage","2025-07-04",{"date":66,"type":67},"2025-07-09","ACTUAL",{"date":69,"type":67},"2025-06-17",{"date":71,"type":54},"2028-07",{"name":5,"class":6},1]